Incremental risk of high-grade adverse events with immune checkpoint inhibitors with or without poly(adenosine diphosphate-ribose) polymerase inhibitors in first-line treatment of advanced endometrial cancer: a systematic review and meta-analysis.

Authors

Mariana Carvalho Gouveia, Helena M Obermair, Mariana Macambira Noronha, Rim Abou Chakra, Louisa Liehn, Marina Rosanu, Arthur Heng-Cheng Hsu, Jose Manuel Estrada-Lorenzo, Ainhoa Madariaga

Published in

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. Pages 104979. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

To evaluate the incremental risk of adverse events associated with immune checkpoint inhibitors, with or without poly(adenosine diphosphate-ribose) polymerase inhibitors, when added to first-line platinum-based chemotherapy for advanced or recurrent endometrial cancer.
We conducted a systematic review and meta-analysis of randomized phase II or III trials evaluating first-line chemo-immunotherapy with or without poly(adenosine diphosphate-ribose) polymerase inhibitors in advanced or recurrent endometrial cancer. PubMed, Embase, and Cochrane databases were searched through October 12, 2025. The primary end point was safety. Pooled risk ratios and 95% confidence intervals were calculated using random-effects models. Sub-group analyses compared doublet therapy (chemotherapy plus an immune checkpoint inhibitor) and triplet therapy (chemotherapy plus an immune checkpoint inhibitor and a poly(adenosine diphosphate-ribose) polymerase inhibitor) with chemotherapy alone.
Six randomized trials involving 2995 patients were included. Neither doublet nor triplet therapy increased the risk of any-grade adverse events compared with chemotherapy alone. Doublet therapy significantly increased grade ≥3 adverse events (risk ratio 1.12, 95% confidence interval 1.02 to 1.24), whereas triplet therapy showed a nonsignificant trend toward increased grade ≥3 toxicity (risk ratio 1.41, 95% confidence interval 0.99 to 2.01). Triplet therapy significantly increased serious adverse events (risk ratio 2.20, 95% confidence interval 1.74 to 2.78), whereas doublet therapy did not. No significant increase in fatal adverse events or treatment discontinuations was observed with either strategy. Both doublet and triplet regimens increased immune-related adverse events, including hypothyroidism. Triplet therapy was associated with a significantly higher risk of grade ≥3 anemia (risk ratio 1.66, 95% confidence interval 1.14 to 2.42), whereas doublet therapy was not. Most immune-related toxicities were low grade, with no clear increase in grade ≥3 immune-related adverse events.
Chemo-immunotherapy demonstrates a manageable safety profile and remains the standard first-line treatment backbone for advanced endometrial cancer. The addition of poly(adenosine diphosphate-ribose) polymerase inhibitors appear to increase serious adverse events and hematologic toxicity, particularly grade ≥3 anemia, without increasing treatment-related mortality. In the absence of validated predictive biomarkers or a demonstrated overall survival benefit, poly(adenosine diphosphate-ribose) polymerase inhibitor-based treatment intensification should be individualized and carefully weighed against its additional toxicity burden.

PMID:
42702517
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.